Product image of Kisplyx (Lenvatinib) supplied by GNH India

Kisplyx

Active Ingredient:
Lenvatinib
Origin:
EU

Kisplyx (Lenvatinib)

Lenvatinib, the active ingredient in Kisplyx, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma in adult patients. The drug works by blocking multiple receptor tyrosine kinases involved in tumor angiogenesis and cell proliferation.

GNH India supplies Kisplyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to stringent regulatory requirements and batch‑to‑batch consistency.

Manufacturer / TM Owner

Eisai Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kisplyx (lenvatinib) targets key signaling pathways in several solid tumours, providing therapeutic benefit across multiple cancer types.

  • Differentiated thyroid cancer: improves progression‑free survival by inhibiting tumor growth and angiogenesis.
  • Renal cell carcinoma: reduces tumor burden and delays disease progression in advanced cases.
  • Hepatocellular carcinoma: slows disease advancement when used in combination with other agents.
  • Endometrial carcinoma: enhances response rates in patients with advanced disease.

How It Works

  • Lenvatinib inhibits multiple receptor tyrosine kinases—including VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT—thereby blocking signaling pathways that drive tumor angiogenesis, proliferation, and survival. This multi‑target inhibition reduces blood vessel formation within tumours and directly suppresses cancer cell growth.

Side Effects

Lenvatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hypertension: elevated blood pressure commonly observed.
  • Diarrhea: frequent loose stools.
  • Fatigue: persistent tiredness.
  • Nausea: feeling of sickness.
  • Decreased appetite: reduced desire to eat.
  • Weight loss: unintended loss of body weight.

Serious or Rare Side Effects

  • Hepatic failure: severe liver injury.
  • Arterial thromboembolism: clot formation in arteries.
  • Severe hemorrhage: significant bleeding events.
  • Gastrointestinal perforation or fistula formation.
  • Life‑threatening hypertension requiring urgent treatment.

Precautions & Warnings

When prescribing Kisplyx, clinicians should observe several safety measures to minimise risk.

  • Monitor blood pressure: check regularly for hypertension, a frequent effect.
  • Assess liver function: perform baseline and periodic liver enzyme tests.
  • Evaluate for proteinuria: urine analysis should be performed periodically.
  • Review concomitant anticoagulant use: increased bleeding risk may occur.
  • Adjust dose in renal impairment: consider reduced dosing in patients with decreased renal function.
  • Store at room temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Lenvatinib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise lenvatinib plasma levels, increasing toxicity.
  • Strong CYP3A4 inducers (e.g., rifampicin): may lower exposure, reducing effectiveness.
  • Anticoagulants (e.g., warfarin): heightened risk of severe bleeding.

Moderate Interactions (Monitor Closely)

  • Antihypertensive agents: blood pressure control may be affected; monitor and adjust doses.
  • Oral contraceptives: efficacy may be reduced; consider alternative contraception.

Frequently Asked Questions

Kisplyx contains lenvatinib and is prescribed for adult patients with differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma. In each indication the drug aims to slow disease progression by inhibiting tumor growth and blood‑vessel formation.

Lenvatinib blocks several receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT. By inhibiting these pathways it reduces angiogenesis, limits nutrient supply to the tumour, and directly suppresses cancer cell proliferation.

The exact dose of Kisplyx is determined by the prescribing physician based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here; dosing follows the approved label and the clinician’s judgment.

Safety of lenvatinib in pregnancy or while nursing has not been established. The drug is generally contraindicated in pregnant or breastfeeding women because of potential fetal toxicity and unknown effects on the infant. Women of child‑bearing potential should use effective contraception.

To order Kisplyx, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kisplyx (lenvatinib) differs from agents such as sorafenib or sunitinib by targeting a broader spectrum of kinases, including FGFRs. This broader inhibition can translate into distinct efficacy profiles in certain cancers, but may also be associated with a unique safety and side‑effect pattern that clinicians must consider.

Kisplyx tablets should be stored at room temperature, below 25 °C, in the original container. Protect the product from moisture, light and excessive heat. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Kisplyx is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water, with or without food, as directed by the prescriber. Consistency in timing and adherence to the prescribed schedule are important for optimal effect.

The most concerning adverse events include severe hypertension, hepatic failure, and arterial thromboembolic events such as stroke or myocardial infarction. Prompt monitoring of blood pressure, liver function tests, and cardiovascular status is essential to detect and manage these risks early.

Kisplyx should be avoided in patients with known hypersensitivity to lenvatinib or any excipients, in those with uncontrolled hypertension, severe hepatic impairment, or in individuals receiving concurrent strong CYP3A4 inducers that could markedly reduce drug exposure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenvatinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT